Revvity, Inc.

NYSE:RVTY Aktierapport

Börsvärde: US$9.7b

Revvity Framtida tillväxt

Future kriterier kontrolleras 3/6

Revvity förväntas öka intäkter och intäkter med 22.8% respektive 5.5% per år. EPS förväntas tillväxt med 23.3% per år. Avkastningen på eget kapital förväntas bli 9% om 3 år.

Viktig information

22.8%

Tillväxttakt i vinsten

23.25%

Tillväxttakt för EPS

Life Sciences vinsttillväxt16.3%
Intäkternas tillväxttakt5.5%
Framtida avkastning på eget kapital9.01%
Bevakning av analytiker

Good

Senast uppdaterad20 Apr 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

RVTY: 2026 Tools Recovery Setup Will Face Mixed Execution Debate

The analyst fair value estimate for Revvity has been reset from $105 to $95, as analysts weigh recent target cuts alongside mixed rating changes and revised assumptions for growth, margins, and future P/E multiples. Analyst Commentary Recent Street research on Revvity has sent mixed signals, with several price target adjustments and at least one downgrade alongside an upgrade.

RVTY: Recent Upgrade Cycle And Q4 Execution Will Drive Future Upside

Revvity's updated analyst price target edges up from $137.63 to $140.00 as analysts factor in a mix of recent target increases from several firms and a more cautious stance from at least one large bank. Analyst Commentary The latest Street research on Revvity reflects a split view, with several bullish analysts lifting price targets and one large bank taking a more cautious approach.

RVTY: 2026 Tools Recovery Setup Will Support Healthier End Markets

Revvity’s analyst price targets have shifted higher by a few dollars across several firms, with analysts pointing to healthier end markets, improving procedure and CapEx trends into 2026, early recovery signs in China, and expectations for the company’s tools exposure as key supports for the updated valuations. Analyst Commentary Recent Street research on Revvity has centered on how much recovery in tools demand and procedure volumes is already reflected in current valuations.

RVTY: 2026 Tools Demand And China Recovery Will Support Higher Earnings Power

Revvity's analyst price target edges higher from $114.63 to $119.56 as analysts factor in updated assumptions around discount rates, modestly slower revenue growth and slightly lower profit margins, along with a higher future P/E multiple supported by a series of recent target raises from Baird, TD Cowen, Evercore ISI, Barclays and Jefferies. Analyst Commentary Bullish analysts have been lifting their price targets in a fairly tight range, which points to a shared view that Revvity's risk or return profile has shifted enough to justify higher valuation assumptions, even as they factor in tempered expectations for revenue growth and margins.

RVTY: Fair Value View Weighs 2026 Recovery Against Policy And China Risks

Analysts have nudged their targets on Revvity higher, with recent $3 to $6 price target increases clustered around a fresh $112 mark. They cite recovering end markets, healthier procedure and CapEx trends into 2026, and early signs of improvement in China as key supports for the updated view.

RVTY: Fair Value View Balances Margin Upside With Policy And China Risks

Analysts have lifted their implied fair value for Revvity by $5 to $105, citing updated assumptions around profit margins, a lower future P/E multiple, and recent price target increases from several firms as key drivers of the recalibration. Analyst Commentary Recent Street research on Revvity has centered on fine tuning price targets and reassessing how much investors are willing to pay for the company, with several firms adjusting their models around margin expectations and appropriate P/E levels.

RVTY: Q4 Margin Ramp And Sector Recovery Thesis Will Drive Upside

Narrative Update Analysts have lifted their price target on Revvity by about US$4 to reflect modestly higher fair value estimates and slightly stronger assumptions for revenue growth, Q4 execution and sector recovery potential into 2026. Analyst Commentary Bullish analysts are leaning constructive on Revvity, pointing to recent quarterly execution, updated guidance and sector trends as support for higher valuation ranges.

RVTY: Q4 Margin Ramp And Buybacks Poised To Meet Cautious Recovery

The analyst price target for Revvity has been nudged higher by about $0.25, reflecting Street analysts' generally constructive view on recovering end markets, Q4 guidance that many see as achievable, and improving sector sentiment, even as some firm specific and China related risks remain in focus. Analyst Commentary Street research on Revvity is mixed but tilts constructive, with several firms nudging price targets higher while one new initiation takes a more cautious stance.

RVTY: Q4 Margin Ramp And Buybacks Will Drive Next Phase

Analysts have nudged their average price target on Revvity modestly higher, reflecting confidence that Q4’s steeper ramp in sales and operating margins is achievable and supported by in-line Q3 organic growth, an earnings beat, and slightly improved forward earnings guidance, despite lingering company specific and macro headwinds. Analyst Commentary Bullish analysts highlight that Q3, while not spectacular, provides a solid springboard for a steeper ramp in Q4 sales and operating margins, which they view as achievable based on in line organic growth and an earnings beat.

Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?

Dec 18
Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?

RVTY Q4 Margin Ramp And Buybacks Will Drive Stronger Future Upside

Analysts have modestly raised their blended price target on Revvity to approximately $105 per share, up from around $100. This change reflects increased confidence that the company can deliver a steeper but achievable ramp in Q4 sales and margins while continuing to improve profitability, despite a slightly higher discount rate and lingering near term growth risks.

RVTY: Buyback Program and Guidance Outlook Will Shape Next Phase

Analysts have increased their price target for Revvity to $105 from previous levels. They cite achievable Q4 guidance and an improved profit outlook, despite mixed quarterly results.

RVTY: Recent Buyback Activity and Expanded Partnership Will Drive Near-Term Momentum

Revvity's analyst price target has increased from $99 to $105 per share, as analysts cite improving guidance for the upcoming quarter and stronger than expected recent performance, while noting that some risks remain. Analyst Commentary Analyst sentiment towards Revvity has shifted positively in recent weeks, reflecting improved financial guidance and resilient performance.

RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead

Analysts have slightly raised their fair value estimate for Revvity by $1 to $113.67. They cite more achievable Q4 guidance and improved margin prospects following the company's recent earnings updates.

Revvity: Software Momentum And Screening Offset China Weakness

Oct 27

Digital Transformation And Advanced Diagnostics Will Create Enduring Value

The consensus analyst price target for Revvity has decreased from $115.19 to $112.67. This change reflects lowered profit margin forecasts, slower revenue growth expectations, and continued market headwinds highlighted in recent research reports.

Digital Transformation And Advanced Diagnostics Will Create Enduring Value

Analysts have slightly reduced their price target for Revvity by $1.63 to $115.19. They cite cautious optimism, as stable core markets are offset by ongoing sector uncertainties and revised forecasts for a slower recovery.

Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings Suggest

Aug 14
Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings Suggest

Investors Interested In Revvity, Inc.'s (NYSE:RVTY) Earnings

Jul 22
Investors Interested In Revvity, Inc.'s (NYSE:RVTY) Earnings

Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101?

Jul 04
Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101?

Revvity: Acquisitions In High-Growth Sectors, Excellent Debt Levels Create Notable Growth Potential

Feb 24

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Dec 16

Prognoser för vinst- och omsättningstillväxt

NYSE:RVTY - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20283,3366557498318
12/31/20273,13341568877715
12/31/20262,97934265073815
12/28/20252,856240509583N/A
9/28/20252,813232497575N/A
6/29/20252,798279503585N/A
3/30/20252,770296524609N/A
12/29/20242,755283542628N/A
9/29/20242,722258564651N/A
6/30/20242,708197383469N/A
3/31/20242,72618397175N/A
12/31/20232,7511801091N/A
10/1/20232,796213-5034N/A
7/2/20232,837250153227N/A
4/2/20233,024353380460N/A
1/1/20233,312513594680N/A
10/2/20223,599599790876N/A
7/3/20223,7486379321,030N/A
4/3/20223,4836941,1221,220N/A
1/2/20223,8288891,3251,411N/A
10/3/20214,1551,0861,4781,557N/A
7/4/20214,2571,1551,3801,455N/A
4/4/20214,4381,0741,2341,306N/A
1/3/20212,663631829892N/A
10/4/20203,234412545625N/A
7/5/20202,977294444521N/A
4/5/20202,887226352429N/A
12/29/20192,884228282363N/A
9/29/20192,835235N/A308N/A
6/30/20192,802251N/A294N/A
3/31/20192,783247N/A320N/A
12/30/20182,778237N/A311N/A
9/30/20182,663128N/A280N/A
7/1/20182,543149N/A245N/A
4/1/20182,387147N/A220N/A
12/31/20172,257157N/A288N/A
10/1/20172,182258N/A309N/A
7/2/20172,142215N/A324N/A
4/2/20172,132210N/A372N/A
1/1/20172,116216N/A351N/A
10/2/20161,999198N/A327N/A
7/3/20162,048199N/A314N/A
4/3/20162,076190N/A281N/A
1/3/20162,105189N/A287N/A
10/4/20152,263176N/A258N/A
6/28/20152,241164N/A261N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: RVTY s prognostiserade vinsttillväxt ( 22.8% per år) är över sparkvoten ( 3.4% ).

Resultat vs marknad: RVTY s intäkter ( 22.8% per år) förväntas växa snabbare än marknaden för US ( 15.8% per år).

Höga tillväxtresultat: RVTY s intäkter förväntas växa avsevärt under de kommande 3 åren.

Intäkt vs marknad: RVTY s intäkter ( 5.5% per år) förväntas växa långsammare än marknaden för US ( 11.1% per år).

Hög tillväxtintäkter: RVTY s intäkter ( 5.5% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: RVTY s avkastning på eget kapital förväntas bli låg om 3 år ( 9 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/01 12:43
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/28
Årlig intjäning2025/12/28

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Revvity, Inc. bevakas av 35 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Catherine Ramsey SchulteBaird
Charles ButlerBarclays
Luke SergottBarclays